Tenpoint Therapeutics, Ltd.

Tenpoint Therapeutics is a global commercial ophthalmic pharmaceutical company based in Irvine, California, dedicated to rejuvenating vision for the aging eye.

We specialize in developing and commercializing innovative treatments for presbyopia, cataracts, and geographic atrophy, addressing the significant unmet needs of millions worldwide. Our mission is to redefine what’s possible in age-related eye care through a patient-centric approach and strategic partnerships with eye care professionals.

Tenpoint Therapeutics leverages a deep understanding of real-world patient experiences and a commitment to scientific rigor to deliver functional near-vision improvements and a durable tolerability profile, ultimately enhancing the quality of life for individuals facing the challenges of aging eyes. We are focused on long-term solutions and are proud to be a leader in this evolving field.

Founded in 2019, Tenpoint Therapeutics has rapidly established a strong leadership team with extensive experience in ophthalmic drug development and commercialization, including FDA acceptance of a new drug application for BRIMOCHOL™ PF. Our commitment to innovation and collaboration is driving the future of eye care.